FN2 Earnings Intelligence
Vertex Pharmaceuticals Incorporated financials
Vertex Pharmaceuticals Incorporated (VRTX) financial statements and key operating metrics from FN2 Research.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $6,795 | $10,504 | $10,369.1 | $4,569.6 | $5,084.8 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $7,574.4 | $8,930.7 | $9,869.2 | $11,020.1 | $12,001.3 | $13,226.3 | $14,578.5 |
| % Growth | 22.1% | 17.9% | 10.5% | 11.7% | 8.9% | 10.2% | 10.2% |
| Gross Profit | $6,670.2 | $7,850.4 | $8,607 | $9,489.6 | $10,350 | - | - |
| % Margin | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% | - | - |
| EBITDA | $2,907.7 | $4,455.7 | $4,013.3 | -$25.7 | $4,383.1 | - | - |
| % Margin | 38.4% | 49.9% | 40.7% | -0.2% | 36.5% | - | - |
| Net Income | $2,342.1 | $3,322 | $3,619.6 | -$535.6 | $3,953.2 | - | - |
| % Margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% | - | - |
| Diluted EPS | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 | $18.75 | $21.19 |
| % Growth | -12.4% | 42.3% | 8.3% | -115.0% | 836.5% | 22.4% | 13.0% |
| Operating Cash Flow | $2,643.5 | $4,129.9 | $3,537.3 | -$492.6 | $3,631.4 | - | - |
| CapEx | $235 | $204.7 | $200.4 | $297.7 | $437.6 | - | - |
| Free Cash Flow | $2,408.5 | $3,925.2 | $3,336.9 | -$790.3 | $3,193.8 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 | 12/31/2026 est. | 12/31/2027 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $7,574.4 | $8,930.7 | $9,869.2 | $11,020.1 | $12,001.3 | $13,226.3 | $14,578.5 |
| Gross Profit | $6,670.2 | $7,850.4 | $8,607 | $9,489.6 | $10,350 | - | - |
| EBITDA | $2,907.7 | $4,455.7 | $4,013.3 | -$25.7 | $4,383.1 | - | - |
| Net Income | $2,342.1 | $3,322 | $3,619.6 | -$535.6 | $3,953.2 | - | - |
| Diluted EPS | $9.01 | $12.82 | $13.89 | -$2.08 | $15.32 | $18.75 | $21.19 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $6,795 | $10,504 | $10,369.1 | $4,569.6 | $5,084.8 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $2,643.5 | $4,129.9 | $3,537.3 | -$492.6 | $3,631.4 |
| Capital Expenditure | $235 | $204.7 | $200.4 | $297.7 | $437.6 |
| Free Cash Flow | $2,408.5 | $3,925.2 | $3,336.9 | -$790.3 | $3,193.8 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2024 | 12/31/2025 |
|---|---|---|---|---|---|
| Revenue Growth | 22.1% | 17.9% | 10.5% | 11.7% | 8.9% |
| Gross Margin | 88.1% | 87.9% | 87.2% | 86.1% | 86.2% |
| EBITDA Margin | 38.4% | 49.9% | 40.7% | -0.2% | 36.5% |
| Net Margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.9% |
| FCF Margin | 31.8% | 44.0% | 33.8% | -7.2% | 26.6% |
| Diluted EPS Growth | -12.4% | 42.3% | 8.3% | -115.0% | 836.5% |